GLP-1 medications and ADHD stimulants: what is known about taking both

More adults taking ADHD medication are also being prescribed semaglutide (Ozempic, Wegovy) or tirzepatide (Mounjaro, Zepbound). It is a fair question whether the two go together. The direct answer is that the research has not been done. This page separates what FDA labels state (checked on DailyMed on November 4, 2026) from what can only be inferred, so you can have a useful conversation with your prescribers. It gives no doses and is not advice to start, stop or change a medication.

What is known about the combination itself

Very little. A PubMed search on November 4, 2026, combining these drugs with ADHD and stimulant terms, found no study of the combination. The searched labels do not name the combination either: the Wegovy, Ozempic, Zepbound and Mounjaro labels do not mention stimulants, and the Adderall XR, Vyvanse and Concerta labels do not mention GLP-1 medications. Those labels also do not list it as prohibited. Silence is not evidence of safety, and it is not evidence of an interaction. Nobody can responsibly quote you a risk figure for taking both.

Label facts: where the effects overlap

Rates come from separate trials and different populations, so they cannot be compared across rows or added together.

Averages also hide individual variation. In Wegovy's trials, a rise of 20 beats per minute or more at any visit was seen in 26% of adults, against 16% on placebo.

Inference, not established fact

The points below are reasoning from labels. No source studied them for this combination, and they should not be read as known interactions.

• Heart rate. Two medications that can each raise heart rate might raise it more together, but no study has measured this.
• Eating and nutrition. Two appetite-reducing drugs could leave some people eating too little. That is plausible, not measured. A 2025 joint advisory from four US nutrition and obesity organizations names nutrient deficiencies from calorie reduction and loss of muscle and bone as challenges of GLP-1 treatment on its own.
• Timing of an oral stimulant. Slower stomach emptying could change how quickly an oral stimulant starts working. The food findings above are not GLP-1 studies, so they only show that some stimulants' peak timing can shift.
• Dehydration and kidneys. GLP-1 labels report acute kidney injury, mostly in people dehydrated by stomach side effects. The Adderall XR label reports reduced amphetamine clearance in severe kidney impairment. Whether these connect in practice is unknown.
• Concerta tablets. The Concerta label says its nondeformable tablet should not ordinarily be used in people with severe narrowing of the digestive tract. The Ozempic and Zepbound labels list ileus and intestinal obstruction among postmarketing reports. No source links the two, but a history of bowel obstruction is worth mentioning.

Delayed stomach emptying and oral medications

The labels are specific about this. The Ozempic label says semaglutide did not affect absorption of the studied oral medications to any clinically relevant degree, but that caution should be used. The Wegovy label reports that levothyroxine exposure rose 33% in a study with semaglutide tablets, and it says to monitor the effects of oral medications. The Zepbound and Mounjaro labels say the delay is largest after the first dose and diminishes over time. They advise monitoring oral drugs that depend on threshold concentrations for efficacy, and they say oral contraceptives may be less effective, so people using them should switch to a non-oral method or add a barrier method for 4 weeks after starting and after each dose increase.

A 2024 systematic review of 22 reports and six prescribing documents found that GLP-1 medications left peak levels of other drugs unchanged or lower and delayed the time to peak, without clinically significant changes in overall exposure. It noted that studies mostly enrolled healthy subjects. Its full text does not mention amphetamine, lisdexamfetamine or methylphenidate. A 2025 review reached a similar conclusion, flagging oral contraceptives and levothyroxine as exceptions. So the general evidence is reassuring, but it does not cover stimulants.

One practical label point: Wegovy tablets are taken in the morning on an empty stomach, with a wait of at least 30 minutes before food, drinks or other oral medications. Adderall XR, Vyvanse and Concerta are morning medications too. If you take both, ask how to time them, and do not rearrange them yourself.

Monitoring to ask about

• Heart rate and blood pressure. The Wegovy label says to monitor heart rate at regular intervals and to tell providers about palpitations or a racing heartbeat at rest. NICE advises checking heart rate and blood pressure before and after each ADHD medication dose change and every six months. Ask whether home readings would help, and ask for a check when either medication changes. See heart and blood pressure safety.
• Weight and food intake. NICE advises weighing adults on ADHD medication every six months and considering BMI monitoring if weight changes. The 2025 advisory recommends baseline screening of dietary habits and management of stomach side effects, and it lists registered dietitian counseling among supportive strategies. Weight loss on a GLP-1 can make it harder to tell which drug is responsible. See ADHD medication, appetite and weight.
• Eating disorders. The advisory lists disordered eating among the things to screen for before starting. Tell both prescribers about any past or current eating disorder. See ADHD and eating disorders.
• ADHD symptom coverage. Note when your stimulant starts and fades, especially during the first weeks of a GLP-1 and after dose increases. See tolerance and wearing off.
• Dehydration. GLP-1 Medication Guides say to tell your provider right away about nausea, vomiting or diarrhea that does not go away.
• Surgery. GLP-1 labels report rare cases of pulmonary aspiration under anesthesia and tell patients to report planned procedures. The Concerta label tells clinicians to avoid it in patients receiving anesthetics on the day of surgery, so ask your surgical team and prescriber what to do. Tell the surgical team about both.

Suicidal thoughts and mood: the current label wording

Wegovy and Zepbound labels used to include a warning on suicidal behavior and ideation. On January 13, 2026, the FDA asked makers of Saxenda, Wegovy and Zepbound to remove it. The FDA cited a meta-analysis of 91 placebo-controlled trials with 107,910 patients and a cohort study of more than 2.2 million new users with type 2 diabetes, neither showing increased risk. The current Wegovy and Zepbound labels show the section as removed in February 2026, as of November 2026. Diabetes labels such as Ozempic did not carry this warning.

The FDA still tells patients to report new or worsening depression, suicidal thoughts or unusual changes in mood. Some ADHD medications have their own mood warnings; see ADHD medication and mood changes. Call or text 988 for thoughts of suicide, and call 911 for emergencies.

Stimulants are not weight-loss drugs

The Vyvanse label says it is not indicated or recommended for weight loss, that other sympathomimetic drugs used for weight loss have been linked to serious cardiovascular events, and that its safety and effectiveness for obesity have not been established. Taking a stimulant in any way other than prescribed is what labels define as misuse. See misuse and addiction risk.

When to call, and when it is urgent

• Call the prescriber for a resting racing heartbeat, unplanned changes in how your ADHD medication works, persistent vomiting or diarrhea, trouble eating enough, or a mood change. Do not stop or change either medication on your own.
• Call 911 or go to the emergency room for chest pain, shortness of breath or fainting, which stimulant Medication Guides list as signs of heart problems.

Questions for your prescribers

• Does each of you know about the other medication?
• Who will track my heart rate, blood pressure and weight, and how often?
• What change would make you want to adjust something?
• How should I time my medications?

Dr. Shershow evaluates and treats adults with ADHD located in New York or New Jersey, including medication management when medication is appropriate. See adult ADHD treatment.